Setting expectations for current and future directions of native mass spectrometry in the biopharmaceutical industry
Academic source · mAbs
Source published: · Event / reporting date: 2026-07-15
Site published: 2026-11-04 · Updated: 2026-11-04
This source is linked automatically. Choose a question to get started.
What the paper reports
This industry perspective examines native mass spectrometry as a complement to established biopharmaceutical characterization methods. It discusses intact assemblies, binding, stoichiometry, and heterogeneity, while identifying throughput, sensitivity, automation, and access limitations. The authors emphasize integration with analytical workflows rather than universal replacement of existing methods.
Why this paper is included
Useful when deciding which characterization questions justify a native-MS workflow.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections